Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(50.0%)
USD 0.15
(50.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.64 Million USD | 0.0% |
| 2022 | -2.64 Million USD | 32.39% |
| 2021 | -3.91 Million USD | -121.88% |
| 2020 | -1.76 Million USD | 86.32% |
| 2019 | -12.88 Million USD | -66.73% |
| 2018 | -7.72 Million USD | 18.34% |
| 2017 | -9.46 Million USD | -40.56% |
| 2016 | -6.73 Million USD | -114.02% |
| 2015 | -3.14 Million USD | 50.98% |
| 2014 | -6.41 Million USD | 52.36% |
| 2013 | -13.47 Million USD | -5.05% |
| 2012 | -12.82 Million USD | -110.29% |
| 2011 | -6.09 Million USD | 0.0% |
| 2009 | -13.84 Million USD | 50.76% |
| 2008 | -28.1 Million USD | 49.14% |
| 2007 | -55.26 Million USD | 29.88% |
| 2006 | -78.81 Million USD | -26.31% |
| 2005 | -62.39 Million USD | -156.67% |
| 2004 | -24.3 Million USD | -98.86% |
| 2003 | -12.22 Million USD | -5.79% |
| 2002 | -11.55 Million USD | -44.94% |
| 2001 | -7.97 Million USD | -56.23% |
| 2000 | -5.1 Million USD | -13.58% |
| 1999 | -4.49 Million USD | 16.97% |
| 1998 | -5.41 Million USD | -58.51% |
| 1997 | -3.41 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -260.65 Thousand USD | 36.11% |
| 2024 Q3 | -1.74 Million USD | -19102.87% |
| 2024 Q2 | 9192.00 USD | 103.53% |
| 2023 FY | - USD | 0.0% |
| 2023 Q3 | -314.7 Thousand USD | 73.78% |
| 2023 Q4 | -407.95 Thousand USD | -29.63% |
| 2023 Q1 | -721.43 Thousand USD | 45.84% |
| 2023 Q2 | -1.2 Million USD | -66.38% |
| 2022 FY | - USD | 32.39% |
| 2022 Q1 | -719.53 Thousand USD | 81.33% |
| 2022 Q2 | -841.47 Thousand USD | -16.95% |
| 2022 Q3 | -1.01 Million USD | -21.03% |
| 2022 Q4 | -1.33 Million USD | -30.8% |
| 2021 Q2 | -787.81 Thousand USD | 27.96% |
| 2021 Q4 | -3.85 Million USD | -361.7% |
| 2021 Q1 | -1.09 Million USD | 2.16% |
| 2021 FY | - USD | -121.88% |
| 2021 Q3 | 1.47 Million USD | 286.95% |
| 2020 Q2 | -1.91 Million USD | 36.74% |
| 2020 Q3 | -1.24 Million USD | 34.86% |
| 2020 Q4 | -1.11 Million USD | 10.44% |
| 2020 FY | - USD | 86.32% |
| 2020 Q1 | -3.02 Million USD | 14.57% |
| 2019 FY | - USD | -66.73% |
| 2019 Q4 | -3.54 Million USD | 5.43% |
| 2019 Q1 | -2.94 Million USD | -38.81% |
| 2019 Q3 | -3.74 Million USD | -41.34% |
| 2019 Q2 | -2.65 Million USD | 9.89% |
| 2018 FY | - USD | 18.34% |
| 2018 Q1 | -1.75 Million USD | 52.73% |
| 2018 Q3 | -2.22 Million USD | -37.42% |
| 2018 Q2 | -1.62 Million USD | 7.67% |
| 2018 Q4 | -2.12 Million USD | 4.91% |
| 2017 Q1 | -2 Million USD | 33.96% |
| 2017 Q2 | -1.81 Million USD | 9.49% |
| 2017 Q3 | -1.93 Million USD | -6.73% |
| 2017 Q4 | -3.71 Million USD | -92.26% |
| 2017 FY | - USD | -40.56% |
| 2016 FY | - USD | -114.02% |
| 2016 Q1 | -762.59 Thousand USD | 24.38% |
| 2016 Q4 | -3.03 Million USD | -83.65% |
| 2016 Q2 | -1.28 Million USD | -69.11% |
| 2016 Q3 | -1.65 Million USD | -27.99% |
| 2015 Q4 | -1 Million USD | 31.72% |
| 2015 FY | - USD | 50.98% |
| 2015 Q3 | -1.47 Million USD | 50.41% |
| 2015 Q2 | -2.97 Million USD | -228.53% |
| 2015 Q1 | 2.31 Million USD | 370.49% |
| 2014 FY | - USD | 52.36% |
| 2014 Q1 | -2.17 Million USD | 45.34% |
| 2014 Q2 | -1.74 Million USD | 19.71% |
| 2014 Q3 | -1.64 Million USD | 5.47% |
| 2014 Q4 | -856.59 Thousand USD | 48.02% |
| 2013 Q2 | -2.56 Million USD | 39.21% |
| 2013 Q4 | -3.97 Million USD | -46.68% |
| 2013 Q3 | -2.7 Million USD | -5.45% |
| 2013 Q1 | -4.22 Million USD | 23.08% |
| 2013 FY | - USD | -5.05% |
| 2012 Q4 | -5.49 Million USD | -45.79% |
| 2012 Q1 | -3 Million USD | -43.53% |
| 2012 FY | - USD | -110.29% |
| 2012 Q3 | -3.76 Million USD | -35.25% |
| 2012 Q2 | -2.78 Million USD | 7.26% |
| 2011 Q4 | -2.09 Million USD | -5.13% |
| 2011 Q2 | -564.52 Thousand USD | 61.1% |
| 2011 Q1 | -1.45 Million USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | -1.99 Million USD | -252.64% |
| 2010 Q3 | -1.05 Million USD | 6.91% |
| 2010 Q2 | -1.13 Million USD | 51.47% |
| 2010 Q1 | -2.33 Million USD | -261.3% |
| 2009 FY | - USD | 50.76% |
| 2009 Q4 | 1.44 Million USD | 158.57% |
| 2009 Q3 | -2.46 Million USD | 69.45% |
| 2009 Q2 | -8.08 Million USD | -43.07% |
| 2009 Q1 | -5.64 Million USD | -54.04% |
| 2008 FY | - USD | 49.14% |
| 2008 Q4 | -3.66 Million USD | 32.21% |
| 2008 Q1 | -4.75 Million USD | -170.53% |
| 2008 Q3 | -5.4 Million USD | 21.94% |
| 2008 Q2 | -6.93 Million USD | -45.68% |
| 2007 Q3 | -6.98 Million USD | 35.37% |
| 2007 Q1 | -12.46 Million USD | 36.44% |
| 2007 FY | - USD | 29.88% |
| 2007 Q4 | 6.74 Million USD | 196.59% |
| 2007 Q2 | -10.8 Million USD | 13.32% |
| 2006 Q1 | -18.23 Million USD | 16.79% |
| 2006 Q4 | -19.6 Million USD | -1.85% |
| 2006 Q3 | -19.25 Million USD | 10.96% |
| 2006 Q2 | -21.62 Million USD | -18.58% |
| 2006 FY | - USD | -26.31% |
| 2005 Q1 | -9.88 Million USD | -5.64% |
| 2005 Q3 | -13.56 Million USD | -11.02% |
| 2005 FY | - USD | -156.67% |
| 2005 Q2 | -12.22 Million USD | -23.6% |
| 2005 Q4 | -21.91 Million USD | -61.53% |
| 2004 Q4 | -9.35 Million USD | -51.01% |
| 2004 Q1 | -4.02 Million USD | -2.55% |
| 2004 Q2 | -5.6 Million USD | -39.29% |
| 2004 Q3 | -6.19 Million USD | -10.58% |
| 2004 FY | - USD | -98.86% |
| 2003 Q2 | -3.11 Million USD | 5.38% |
| 2003 Q1 | -3.29 Million USD | -13.16% |
| 2003 Q4 | -3.92 Million USD | -26.45% |
| 2003 FY | - USD | -5.79% |
| 2003 Q3 | -3.1 Million USD | 0.48% |
| 2002 Q1 | -2.56 Million USD | -11.19% |
| 2002 FY | - USD | -44.94% |
| 2002 Q3 | -3.02 Million USD | 2.1% |
| 2002 Q4 | -2.91 Million USD | 3.87% |
| 2002 Q2 | -3.09 Million USD | -20.72% |
| 2001 FY | - USD | -56.23% |
| 2001 Q4 | -2.3 Million USD | 10.41% |
| 2001 Q3 | -2.57 Million USD | -57.48% |
| 2001 Q2 | -1.63 Million USD | -12.07% |
| 2001 Q1 | -1.45 Million USD | 9.32% |
| 2000 Q1 | -900.96 Thousand USD | 43.4% |
| 2000 Q3 | -1.29 Million USD | -8.48% |
| 2000 FY | - USD | -13.58% |
| 2000 Q4 | -1.6 Million USD | -23.85% |
| 2000 Q2 | -1.19 Million USD | -32.82% |
| 1999 Q1 | -1.19 Million USD | 21.59% |
| 1999 Q2 | -1.02 Million USD | 13.79% |
| 1999 Q4 | -1.59 Million USD | -57.24% |
| 1999 Q3 | -1.01 Million USD | 1.69% |
| 1999 FY | - USD | 16.97% |
| 1998 Q2 | -1.3 Million USD | -27.68% |
| 1998 Q3 | -1.36 Million USD | -4.73% |
| 1998 Q1 | -1.02 Million USD | 0.0% |
| 1998 FY | - USD | -58.51% |
| 1998 Q4 | -1.52 Million USD | -11.37% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.277% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 55.397% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.877% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 84.776% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.812% |
| Mesoblast Limited | -62.38 Million USD | 95.761% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -72.159% |
| Genus plc | 73.7 Million USD | 103.588% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 60.002% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 25.445% |
| Marizyme, Inc. | -34.28 Million USD | 92.286% |
| ContraFect Corporation | -64.99 Million USD | 95.932% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 69.854% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 41.575% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -88.646% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -13.797% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -410.466% |
| Accustem Sciences Inc. | -3.74 Million USD | 29.414% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.517% |
| EV Biologics, Inc. | -1.26 Million USD | -108.696% |
| Q BioMed Inc. | -617.62 Thousand USD | -328.162% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 174.033% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -318.157% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -15.757% |
| Biomind Labs Inc. | -1.03 Million USD | -155.614% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 126.774% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 63.073% |
| Skye Bioscience, Inc. | -13.54 Million USD | 80.48% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -77.789% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -10477.792% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 31.92% |
| IMV Inc. | -35.52 Million USD | 92.556% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 83.337% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -5.695% |
| GB Sciences, Inc. | -1.41 Million USD | -86.244% |
| Alpha Cognition Inc. | -9.7 Million USD | 72.753% |
| HST Global, Inc. | -5303.00 USD | -49767.019% |
| CSL Limited | 4.78 Billion USD | 100.055% |
| Halberd Corporation | -74.27 Thousand USD | -3460.156% |
| Enzolytics Inc. | -2.12 Million USD | -24.619% |
| Resverlogix Corp. | -11.74 Million USD | 77.479% |
| Affymax, Inc. | -14.29 Million USD | 81.501% |
| SYBLEU INC | -141.57 Thousand USD | -1767.931% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 13.665% |
| argenx SE | -216.02 Million USD | 98.776% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.221% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 317.292% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -76.425% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 798.031% |
| AVAX Technologies, Inc. | -6.11 Million USD | 56.738% |
| Zenith Capital Corp. | -8.6 Million USD | 69.272% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.937% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -15079.657% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -8.093% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1402.319% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.328% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 8.57% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -152.74% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 39428.495% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -51.111% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -37.666% |
| BioStem Technologies, Inc. | -7.55 Million USD | 64.991% |
| ONE Bio Corp. | 13.61 Million USD | 119.426% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1360.311% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -28.558% |
| Agentix Corp. | -1.37 Million USD | -92.778% |
| LadRx Corporation | 412.28 Thousand USD | 741.416% |
| Cell Source, Inc. | -4.27 Million USD | 38.106% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -620.124% |
| Regen BioPharma, Inc. | 1.46 Million USD | 280.391% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -182.24% |
| NovAccess Global Inc. | -1.03 Million USD | -155.552% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 129.868% |
| Itoco Inc. | -1.86 Million USD | -41.49% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -596.604% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -136.958% |
| Kadimastem Ltd | -2.62 Million USD | -0.765% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1005.77% |
| CytoDyn Inc. | -18.02 Million USD | 85.332% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3246.174% |
| Mobile Lads Corp. | -2.24 Million USD | -17.995% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -21524.401% |
| Qrons Inc. | -40.08 Thousand USD | -6497.76% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -444.486% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 601.381% |
| Rebus Holdings, Inc. | -951 Thousand USD | -178.07% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -149.004% |
| International Stem Cell Corporation | 202 Thousand USD | 1409.133% |
| Bioxytran, Inc. | -3.82 Million USD | 30.776% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4923.647% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -7.414% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 92.627% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5776.551% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 3.417% |
| Neutra Corp. | -181.24 Thousand USD | -1359.03% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 86.882% |
| PureTech Health plc | -11.62 Million USD | 77.256% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 86.881% |
| IXICO plc | -707 Thousand USD | -274.038% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 65.589% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.53% |
| CSL Limited | 4.73 Billion USD | 100.056% |
| Cellectis S.A. | -92.63 Million USD | 97.145% |